Literature DB >> 26796926

Visual Hallucinations in Eye Disease and Lewy Body Disease.

Prabitha Urwyler1, Tobias Nef2, René Müri3, Neil Archibald4, Selina Margaret Makin5, Daniel Collerton6, John-Paul Taylor7, David Burn7, Ian McKeith7, Urs Peter Mosimann8.   

Abstract

OBJECTIVES: Visual hallucinations (VH) most commonly occur in eye disease (ED), Parkinson disease (PD), and Lewy body dementia (LBD). The phenomenology of VH is likely to carry important information about the brain areas within the visual system generating them.
METHODS: Data from five controlled cross-sectional VH studies (164 controls, 135 ED, 156 PD, 79 [PDD 48 + DLB 31] LBD) were combined and analyzed. The prevalence, phenomenology, frequency, duration, and contents of VH were compared across diseases and sex.
RESULTS: Simple VH were most common in ED patients (ED 65% versus LBD 22% versus PD 9%, χ(2) = 31.43, df = 2, p < 0.001), whereas complex VH were more common in LBD (LBD 76% versus ED 38%, versus PD 28%, χ(2) = 96.80, df = 2, p < 0.001). The phenomenology of complex VH was different across diseases and sex. ED patients reported more "flowers" (ED 21% versus LBD 6% versus PD 0%, χ(2) = 10.04, df = 2, p = 0.005) and "body parts" (ED 40% versus LBD 17% versus PD 13%, χ(2) = 11.14, df = 2, p = 0.004); in contrast, LBD patients reported "people" (LBD 85% versus ED 67% versus PD 63%, χ(2) = 6.20, df = 2, p = 0.045) and "animals/insects" (LBD 50% versus PD 42% versus ED 21%, χ(2) = 9.76, df = 2, p = 0.008). Men reported more "machines" (13% versus 2%, χ(2) = 6.94, df = 1, p = 0.008), whereas women reported more "family members/children" (48% versus 29%, χ(2) = 5.10, df = 1, p = 0.024).
CONCLUSIONS: The phenomenology of VH is likely related to disease-specific dysfunctions within the visual system and to past, personal experiences.
Copyright © 2016 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lewy body dementia; Parkinson disease; Visual hallucinations; eye disease; phenomenology

Mesh:

Year:  2015        PMID: 26796926     DOI: 10.1016/j.jagp.2015.10.007

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  5 in total

1.  Occurrence and phenomenology of hallucinations in the general population: A large online survey.

Authors:  Mascha M J Linszen; Janna N de Boer; Maya J L Schutte; Marieke J H Begemann; Jacqueline de Vries; Sanne Koops; Renske E Blom; Marc M Bohlken; Sophie M Heringa; Jan Dirk Blom; Iris E C Sommer
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-23

2.  Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.

Authors:  Kelsey A Holiday; Eva Pirogovsky-Turk; Vanessa L Malcarne; J Vincent Filoteo; Irene Litvan; Stephanie L Lessig; David Song; Dawn M Schiehser
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

Review 3.  Treatment of Visual Disorders in Parkinson Disease.

Authors:  Joseph Savitt; Michaela Mathews
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

4.  Reduced occipital GABA in Parkinson disease with visual hallucinations.

Authors:  Michael J Firbank; Jehill Parikh; Nicholas Murphy; Alison Killen; Charlotte L Allan; Daniel Collerton; Andrew M Blamire; John-Paul Taylor
Journal:  Neurology       Date:  2018-07-18       Impact factor: 9.910

Review 5.  Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management.

Authors:  John O'Brien; John Paul Taylor; Clive Ballard; Roger A Barker; Clare Bradley; Alistair Burns; Daniel Collerton; Sonali Dave; Rob Dudley; Paul Francis; Andrea Gibbons; Kate Harris; Vanessa Lawrence; Iracema Leroi; Ian McKeith; Michel Michaelides; Chaitali Naik; Claire O'Callaghan; Kirsty Olsen; Marco Onofrj; Rebecca Pinto; Gregor Russell; Peter Swann; Alan Thomas; Prabitha Urwyler; Rimona Sharon Weil; Dominic Ffytche
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-25       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.